EDSA on Nasdaq

Edesa Biotech, Inc.

Canadian pharmaceutical preparations company based in Markham.

Price unavailable

Last updated Oct 18, 2026.

Overview

-$7.2MNet income, fiscal 2025²

Compare with PROVECTUS BIOPHARMACEUTICALS, INC., Allarity Therapeutics, Inc. or Vyome Holdings, Inc, or pick any stock.

TickerEDSA on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersA1
Incorporated inBritish Columbia, Canada³
Business addressC/O Fasken Martineau Dumoulin Llp, 333 Bay Street, Suite 2400, Toronto, M5H 2T6³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-100.0%Revenue growth, 2021⁴

-102.2%Return on equity⁵

-$13.7MFree cash flow⁶

Financial statements

Revenue⁷⁴$0 in 2021

Operating income⁷⁴⁶-$23.7M in 2021+366% since 2018

Net income⁷⁴⁶-$13.3M in 2021+165% since 2018

Every line of the income statement as filed: the last 2 fiscal years, latest first.²

Period ending	2025-09-30	2024-09-30
Research and development	$3.7M	$2.9M
General and administrative	$4.2M	$4.1M
Loss from operations	-$7.9M	-$7.0M
Reimbursement grant income	$783.9K	$698.3K
Interest income	$2.6K	$153.5K
Misc other income	$0	$14.8K
Foreign exchange loss	-$59.6K	-$21.0K
Nonoperating Income (Expense)	$726.8K	$845.5K
Loss before income taxes	-$7.2M	-$6.2M
Income tax expense	$800	$800
Net loss	-$7.2M	-$6.2M
Exchange differences on translation	$76.8K	-$28.0K
Net comprehensive loss	-$7.1M	-$6.2M
Weighted average number of common shares (in shares)	5.7M shares	3.2M shares
Loss per common share - basic and diluted (in dollars per share)	-$1.27	-$1.93

Total assets⁷¹¹⁴⁶$14.6M in 2021+24% since 2018

Total liabilities¹¹⁴⁶$1.5M in 2021+231% since 2019

Shareholders’ equity¹¹⁴⁶⁵$13.1M in 2021+306% since 2018

Cash¹¹⁴⁶$7.8M in 2021+133% since 2018

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.²

Period ending	2025-09-30	2024-09-30	2023-09-30
Cash and cash equivalents	$10.8M	$1.0M
Accounts and other receivable	$642.9K	$270.9K
Prepaid expenses and other current assets	$77.8K	$367.4K
Total current assets	$11.5M	$1.7M
Long-term deposits	$40.0K	$41.2K
Intangible asset, net	$2.0M	$2.1M
Right-of-use assets	$0	$18.4K
Total assets	$13.5M	$3.8M
Current liabilities:	$1.1M	$1.8M
Short-term right-of-use lease liabilities	$0	$19.9K
Total current liabilities	$1.1M	$1.8M
Authorized unlimited common and preferred shares without par value issued and outstanding: 7,141,783 common shares (September 30, 2024 - 3,247,389)	$54.5M	$47.2M
Additional paid-in capital	$14.8M	$13.6M
Accumulated other comprehensive loss	-$165.8K	-$242.6K
Accumulated deficit	-$65.9M	-$58.6M
Total shareholders' equity	$12.5M	$2.0M	$7.0M
Total liabilities and shareholders' equity	$13.5M	$3.8M
Common Stock, No Par Value (in dollars per share)	$0	$0
Common Stock, Shares, Outstanding (in shares)	7.1M shares	3.2M shares
Issued and outstanding: 3,075,473 common shares (September 30, 2022 - 2,380,280) (in shares)	7.1M shares	3.2M shares

Period ending	2025-09-30	2024-09-30	2023-09-30
Cash and cash equivalents	$10.8M	$1.0M
Accounts and other receivable	$642.9K	$270.9K
Prepaid expenses and other current assets	$77.8K	$367.4K
Total current assets	$11.5M	$1.7M
Long-term deposits	$40.0K	$41.2K
Intangible asset, net	$2.0M	$2.1M
Right-of-use assets	$0	$18.4K
Total assets	$13.5M	$3.8M
Current liabilities:	$1.1M	$1.8M
Short-term right-of-use lease liabilities	$0	$19.9K
Total current liabilities	$1.1M	$1.8M
Authorized unlimited common and preferred shares without par value issued and outstanding: 7,141,783 common shares (September 30, 2024 - 3,247,389)	$54.5M	$47.2M
Additional paid-in capital	$14.8M	$13.6M
Accumulated other comprehensive loss	-$165.8K	-$242.6K
Accumulated deficit	-$65.9M	-$58.6M
Total shareholders' equity	$12.5M	$2.0M	$7.0M
Total liabilities and shareholders' equity	$13.5M	$3.8M
Common Stock, No Par Value (in dollars per share)	$0	$0
Common Stock, Shares, Outstanding (in shares)	7.1M shares	3.2M shares
Issued and outstanding: 3,075,473 common shares (September 30, 2022 - 2,380,280) (in shares)	7.1M shares	3.2M shares

Cash from operations⁷⁴⁶-$13.7M in 2021+196% since 2018

Capital spending⁷⁴⁶$6.1K in 2021−98% since 2018

Free cash flow⁷⁴⁶-$13.7M in 2021+174% since 2018

Every line of the cash flow as filed: the last 2 fiscal years, latest first.²

Period ending	2025-09-30	2024-09-30
Net loss	-$7.2M	-$6.2M
Depreciation and amortization	$119.3K	$186.0K
Share-based compensation	$729.6K	$537.5K
Gain on loan forgiveness	$0	-$14.8K
Accounts and other receivable	-$378.0K	$356.3K
Prepaid expenses and other current assets	$107.8K	$197.1K
Accounts payable and accrued liabilities	-$715.5K	$17.6K
Net cash used in operating activities	-$7.3M	-$4.9M
Proceeds from issuance of common shares and warrants	$7.7M	$729.4K
Proceeds from issuance of Series A-1 preferred shares and warrants	$1.5M	$0
Payment for issuance costs of warrants	-$23.4K	$0
Repayment of debt	$0	-$29.5K
Net cash provided by financing activities	$17.0M	$592.0K
Effect of exchange rate changes on cash and cash equivalents	$46.2K	-$25.9K
Net change in cash and cash equivalents	$9.8M	-$4.3M

Compare Edesa Biotech, Inc. with another company

Leadership

Who has led Edesa Biotech, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Mary Catherine Brisson2014–2015

201520202025

Chief executive officerPardeep Nijhawan Jun 11, 2019 to now¹²
Chief executive officerFrank R. Oakes Sep 26, 2014 to Mar 11, 2019¹³
PresidentMichael J. Brooks Jun 11, 2019 to now¹⁴
PresidentFrank R. Oakes Sep 26, 2014 to Mar 11, 2019¹³
Chief financial officerPeter J. Weiler May 2, 2025 to now¹⁵
Chief financial officerStephen Lemieux Jul 17, 2023 to Aug 4, 2023¹⁶
Chief financial officerKathi Niffenegger Sep 25, 2014 to Nov 4, 2022¹⁷
Chief operating officerMary Catherine Brisson Sep 25, 2014 to Dec 23, 2015¹⁸

Board members and other officers (19)

EVP, Corporate DevelopmentGregory T. Baxter Mar 29, 2017 to Mar 14, 2018¹⁹
Chief Technology OfficerHerbert S. Chow Sep 25, 2014 to Oct 3, 2014²⁰
OfficerMark A. McPartland Sep 25, 2014 to Dec 23, 2015²¹
OfficerFrank R. Oakes Dec 15, 2014 to Dec 15, 2014²²
Board memberDa David Liu Feb 18, 2025 to now²³
Board memberJoan Chypyha May 24, 2023 to now²⁴
Board memberPatrick Marshall May 24, 2023 to now²⁵
Board memberJennifer M. Chao Mar 30, 2022 to Mar 30, 2022²⁶
Board memberCarlo Sistilli Jun 11, 2019 to now²⁷
Board memberLorin K. Johnson Jun 11, 2019 to Mar 7, 2022²⁸
Board memberPardeep Nijhawan Jun 11, 2019 to now¹²
Board memberPaul William Pay Jun 11, 2019 to Mar 7, 2022²⁹
Board memberDeborah F. Aghib Jan 25, 2018 to Mar 13, 2019³⁰
Board memberPaul Chun Dec 13, 2016 to Mar 13, 2019³¹
Board memberGregory T. Baxter Sep 25, 2014 to Nov 13, 2014³²
Board memberMayank D. Sampat Sep 25, 2014 to Mar 13, 2019³³
Board memberTessie M. Che Sep 25, 2014 to Mar 13, 2019³⁴
Board memberFrank R. Oakes Sep 26, 2014 to Jul 24, 2023¹³
Board memberDaniel E. Morse Oct 3, 2014 to Apr 3, 2018³⁵

Former names

Stellar Biotechnologies, Inc.Feb 3, 2012 to May 30, 2019³

Timeline

Jun 11, 2019New chief executive Pardeep Nijhawan becomes CEO¹²
Sep 26, 2014New chief executive Frank R. Oakes becomes CEO¹³

Filings

286 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 55 major events, 122 insider forms, 29 large holders, 3 private raises, 55 other. The latest 20:

Oct 15, 20268-K EDGAR
Oct 6, 20264 EDGAR
Sep 1, 20264 EDGAR
Aug 26, 2026SCHEDULE 13G EDGAR
Aug 25, 2026SCHEDULE 13D/A EDGAR
Aug 25, 2026SCHEDULE 13D/A EDGAR
Aug 20, 20268-K EDGAR
Aug 20, 2026424B5 EDGAR
Aug 19, 2026424B5 EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 20268-K EDGAR
Aug 4, 20264 EDGAR
Jul 13, 2026EFFECT EDGAR
Jul 13, 2026424B3 EDGAR
Jul 2, 20264 EDGAR
Jul 2, 2026S-3 EDGAR
Jun 26, 2026D EDGAR
Jun 18, 2026SCHEDULE 13G EDGAR
Jun 16, 2026SCHEDULE 13D/A EDGAR
Jun 16, 20264 EDGAR

The 286 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 29 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jun 16, 2026Raised $3.5 million in a private offering of equity Form D: $3.5 million offered in all Form D
Feb 12, 2025Raised $15 million in a private offering of equity Form D: 15 investors so far Form D
Mar 21, 2022Filed a private offering of securities Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 33. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Velan Capital Investment Management LP	827,500	$6.7M	4.1%	No change
Rubric Capital Management LP	669,500	$5.4M	0.0%	−18,000
Perceptive Advisors LLC	563,239	$4.6M	0.1%	No change
Millennium Management LLC	561,751	$4.6M	0.0%	New
Stonepine Capital Management, LLC	456,439	$3.2M	2.4%	+426,439
Boxer Capital Management, LLC	205,000	$1.7M	0.1%	New
Vanguard Capital Management LLC	81,839	$665.4K	0.0%	−4,127
Geode Capital Management, LLC	80,879	$657.6K	0.0%	+3,825
Jane Street Group, LLC	72,465	$589.1K	0.0%	−43,256
Vanguard Fiduciary Trust Co	38,718	$314.8K	0.0%	+272
State Street Corp	37,979	$308.8K	0.0%	No change
XTX Topco Ltd	35,352	$287.4K	0.0%	New
BlackRock, Inc.	27,495	$223.5K	0.0%	−214
Northern Trust Corp	14,994	$121.9K	0.0%	No change
Scotia Capital Inc.	14,393	$117.0K	0.0%	−1,450
Two Sigma Investments, LP	14,032	$114.1K	0.0%	New
UBS Group AG	6,763	$55.0K	0.0%	+4,420
SBI Securities Co., Ltd.	3,505	$28.5K	0.0%	+3
Federation des caisses Desjardins du Quebec	2,595	$21.1K	0.0%	New
Royal Bank Of Canada	1,851	$15.0K	0.0%	+192
Mcguire Capital Advisors Inc	1,500	$12.2K	0.0%	No change
Morgan Stanley	1,400	$11.4K	0.0%	New
Tower Research Capital LLC (TRC)	1,230	$10.0K	0.0%	+723
Bnp Paribas Financial Markets	1,122	$9.1K	0.0%	New
Jpmorgan Chase & Co	1,130	$8.7K	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREdesa Biotech, Inc. filings on SEC EDGAR
2
SEC EDGAREdesa Biotech, Inc. 10-K for fiscal 2025
3
SEC EDGAREdesa Biotech, Inc. filings on SEC EDGAR
4
SEC EDGAREdesa Biotech, Inc. 10-K for fiscal 2021
5
SEC EDGAREdesa Biotech, Inc. 10-K for fiscal 2021
6
SEC EDGAREdesa Biotech, Inc. 10-K for fiscal 2021
7
SEC EDGAREdesa Biotech, Inc. 10-K for fiscal 2018
8
SEC EDGAREdesa Biotech, Inc. 10-Q for fiscal 2025
9
SEC EDGAREdesa Biotech, Inc. 10-Q for fiscal 2026
10
SEC EDGAREdesa Biotech, Inc. 10-Q for fiscal 2026
11
SEC EDGAREdesa Biotech, Inc. 10-K for fiscal 2019
12
SEC EDGARPardeep Nijhawan, Chief executive officer
13
SEC EDGARFrank R. Oakes, Chief executive officer
14
SEC EDGARMichael J. Brooks, President
15
SEC EDGARPeter J. Weiler, Chief financial officer
16
SEC EDGARStephen Lemieux, Chief financial officer
17
SEC EDGARKathi Niffenegger, Chief financial officer
18
SEC EDGARMary Catherine Brisson, Chief operating officer
19
SEC EDGARGregory T. Baxter, EVP, Corporate Development
20
SEC EDGARHerbert S. Chow, Chief Technology Officer
21
SEC EDGARMark A. McPartland, Officer
22
SEC EDGARFrank R. Oakes, Officer
23
SEC EDGARDa David Liu, Board member
24
SEC EDGARJoan Chypyha, Board member
25
SEC EDGARPatrick Marshall, Board member
26
SEC EDGARJennifer M. Chao, Board member
27
SEC EDGARCarlo Sistilli, Board member
28
SEC EDGARLorin K. Johnson, Board member
29
SEC EDGARPaul William Pay, Board member
30
SEC EDGARDeborah F. Aghib, Board member
31
SEC EDGARPaul Chun, Board member
32
SEC EDGARGregory T. Baxter, Board member
33
SEC EDGARMayank D. Sampat, Board member
34
SEC EDGARTessie M. Che, Board member
35
SEC EDGARDaniel E. Morse, Board member